Stay updated on Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial
Sign up to get notified when there's something new on the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page.

Latest updates to the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page
- ChecktodayChange DetectedUpdated the page revision from v3.0.1 to v3.0.2 and removed the Back to Top element.SummaryDifference0.2%
- Check8 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%
- Check15 days agoChange DetectedThe web page has been updated to include a new facility name, location details, and a list of publications related to pegcetacoplan treatment for geographic atrophy in age-related macular degeneration. Additionally, the revision number has been updated to v3.0.0.SummaryDifference6%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check36 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page.